eketamine nasal spray

Pharma giant Johnson & Johnson (NYSE:JNJ) announced Monday it had asked the Food and Drug Administration (FDA) to approve its nasal spray as a monotherapy for treatment-resistant depression (TRD) in adults. The New Jersey-based company's Spravato, contains esketamine as an active ingredient,...